Skip to main content

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

THIM Hogeschool voor Fysiotherapie heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL. Heb je een vraag, neem dan contact op met helpdesk@thim.nl.

Registreer

Om ook buiten de locaties van THIM, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van THIM.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Top
Gepubliceerd in:

01-01-2008 | Case report

Rapid oral desensitisation procedure in clopidogrel hypersensitivity

Auteurs: B. Oppedijk, D. A. M. Odekerken, J. J. van der Wildt, C. F. Melissant

Gepubliceerd in: Netherlands Heart Journal | Uitgave 1/2008

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

We describe a patient who developed generalised pruritis with oedema and rash two weeks after she had started taking clopidogrel following coronary stent implantation. In the absence of other likely causative agents, clopidogrel hypersensitivity was probable. She was treated with a rapid oral desensitisation procedure, after which a daily dose of 75 mg clopidogrel was well tolerated. No major adverse events occurred during a follow-up period of eight months. Oral desensitisation in clopidogrel hypersensitivity seems to be a safe method to reduce the risk of coronary stent thrombosis. (Neth Heart J 2008;16:21-3).
Literatuur
1.
go back to reference Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Plateletactive drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl):234S-264S. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Plateletactive drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(suppl):234S-264S.
2.
go back to reference McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21.
3.
go back to reference Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, et al. Thirty day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:947-53. Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA, Sonnenschein K, et al. Thirty day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:947-53.
4.
go back to reference Gowda RM, Misra D, Khan IA. Hypersensitivity skin rash: an adverse drug reaction to clopidogrel loading dose. Int J Cardiol 2004;95:333. Gowda RM, Misra D, Khan IA. Hypersensitivity skin rash: an adverse drug reaction to clopidogrel loading dose. Int J Cardiol 2004;95:333.
5.
go back to reference Comert A, Akgun S, Civelek A, Kavala M, Sarigül S, Yildirim T, et al. Clopidogrel-induced hypersensitivity syndrome associated with febrile pancytopenia. Int J Dermatol 2005;44:882-4. Comert A, Akgun S, Civelek A, Kavala M, Sarigül S, Yildirim T, et al. Clopidogrel-induced hypersensitivity syndrome associated with febrile pancytopenia. Int J Dermatol 2005;44:882-4.
6.
go back to reference Doogue MP, Begg EJ, Bridgman P. Clopidogrel Hypersensitivity Syndrome With Rash, Fever, and Neutropenia. Mayo Clin Proc 2005;80:1386-70. Doogue MP, Begg EJ, Bridgman P. Clopidogrel Hypersensitivity Syndrome With Rash, Fever, and Neutropenia. Mayo Clin Proc 2005;80:1386-70.
7.
go back to reference Ten Berg JM, van Werkum JW, Heestermans AACM, Jaarsma W, Hautvast RMA, den Heijer P, et al. Antiplatelet therapy in patients undergoing coronary stenting – the risk of late stent thrombosis. Neth Heart J 2006;14:297-300. Ten Berg JM, van Werkum JW, Heestermans AACM, Jaarsma W, Hautvast RMA, den Heijer P, et al. Antiplatelet therapy in patients undergoing coronary stenting – the risk of late stent thrombosis. Neth Heart J 2006;14:297-300.
8.
go back to reference Van Werkum JW, Heestermans AACM, Jaarsma W, Hautvas RWM, de Boer MJ, ten Berg JM. Trombose van een coronaire stent na het staken van behandeling met clopidogrel. Ned Tijdschr Geneeskd 2006;150:863-8. Van Werkum JW, Heestermans AACM, Jaarsma W, Hautvas RWM, de Boer MJ, ten Berg JM. Trombose van een coronaire stent na het staken van behandeling met clopidogrel. Ned Tijdschr Geneeskd 2006;150:863-8.
9.
go back to reference Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
10.
go back to reference World Health Organization: Adverse events following immunization (AEFI): causality assessment. http://www.who.int/vaccinesdocuments/DocsPDF05/815.pdf. World Health Organization: Adverse events following immunization (AEFI): causality assessment. http://​www.​who.​int/​vaccinesdocument​s/​DocsPDF05/​815.​pdf.​
11.
go back to reference Szto GY, Linnemeier TJ, Ball MW. Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. Am J Cardiol 1999;83:138-9. Szto GY, Linnemeier TJ, Ball MW. Fatal neutropenia and thrombocytopenia associated with ticlopidine after stenting. Am J Cardiol 1999;83:138-9.
12.
go back to reference Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitisation procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 2005;95:509-10. Silberman S, Neukirch-Stoop C, Steg PG. Rapid desensitisation procedure for patients with aspirin hypersensitivity undergoing coronary stenting. Am J Cardiol 2005;95:509-10.
13.
go back to reference Camara MG, Almeda FQ. Clopidogrel (Plavix) desensitisation: a case series. Cathet Cardiovasc Intervent 2005;65:525-7. Camara MG, Almeda FQ. Clopidogrel (Plavix) desensitisation: a case series. Cathet Cardiovasc Intervent 2005;65:525-7.
14.
go back to reference Lee-Wong M, Gadhvi D, Resnick S. Clopidogrel desensitization. Ann Allergy Asthma Immunol 2006;96:756-7. Lee-Wong M, Gadhvi D, Resnick S. Clopidogrel desensitization. Ann Allergy Asthma Immunol 2006;96:756-7.
15.
go back to reference Walker NE, Fasano MB, Horwitz PA. Rapid Communication: Desensitization for the Management of Clopidogrel Hypersensitivity: Initial Clinical Experience. J Invasive Cardiol 2006;18:341-44. Walker NE, Fasano MB, Horwitz PA. Rapid Communication: Desensitization for the Management of Clopidogrel Hypersensitivity: Initial Clinical Experience. J Invasive Cardiol 2006;18:341-44.
Metagegevens
Titel
Rapid oral desensitisation procedure in clopidogrel hypersensitivity
Auteurs
B. Oppedijk
D. A. M. Odekerken
J. J. van der Wildt
C. F. Melissant
Publicatiedatum
01-01-2008
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Netherlands Heart Journal / Uitgave 1/2008
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI
https://doi.org/10.1007/BF03086112